Per N.
- Country
- Sweden
- Department
- BOND Oncology
Research Overview
- Evaluation of Hyperfractionated-Accelerated Radiotherapy and High-Dose Thiotepa Therapy in High-Risk Medulloblastoma Patients Aged Over 3 Years
- Evaluation of Carboplatin and Chemotherapeutic Regimen in Pediatric Patients with Standard-Risk and High-Risk Medulloblastoma: A Multinational Prospective Study
- Phase II Evaluation of Metronomic and Targeted Anti-Angiogenic Therapy with Bevacizumab in Pediatric Recurrent/Progressive Medulloblastoma, Ependymoma, and ATRT
Data & Insights
Has run more than one trial at 97 of 162 partner sites.
Specializations
Pediatric Brain Tumors
This investigator specializes in treating complex pediatric brain malignancies, with particular emphasis on medulloblastoma and its various molecular subtypes including SHH subgroup and non-SHH/non-WNT variants.
- High-risk medulloblastoma management
- Molecular subtype classification
- Risk-adapted treatment approaches
Their expertise extends to evaluating innovative therapeutic strategies for different risk groups within medulloblastoma patients.
Advanced Treatment Modalities
The investigator focuses on evaluating sophisticated treatment approaches including hyperfractionated-accelerated radiotherapy and high-dose therapy protocols for brain tumor management.
- Radiation therapy optimization
- Combined modality treatments
- Maintenance chemotherapy protocols
Their work encompasses the development of targeted therapeutic strategies for specific patient populations.
Rare Pediatric Cancers
The investigator has dedicated expertise in treating atypical teratoid/rhabdoid tumors (ATRT), implementing age-specific treatment protocols for this rare and aggressive childhood cancer.
- Age-adapted treatment strategies
- High-dose chemotherapy protocols
- Consolidation therapy approaches
Their research includes evaluating various consolidation therapies for different age groups affected by ATRT.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.